OXFORD, UK and MASON, OHIO, USA – 30 May 2025 – Following the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, Oxford Cancer Biomarkers Ltd (OCB), a leader in molecular precision cancer diagnostic tests, has today announced a new…
OXFORD, UK – 14th January 2025 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has successfully met a major milestone with recruitment of the first patient into the clinical utility study of its precision oncology…
OXFORD, UK – 3rd April 2023 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has successfully closed its latest investment round. Plutus Investment Group LLP led the round, with participation from new and existing investors…
Today, Oxford Cancer Biomarkers are pleased to announce the publication of the ToxNav ® clinical validation study in the journal Cancers. This milestone represents a significant step forward for OCB and the ToxNav ® brand. ToxNav ® is OCB’s flag…
Professors David and Rachel Kerr’s proposed colorectal cancer treatment guidelines for patients during the COVID-19 era. AIMS METHODS We have modified the guidelines in such a way that we believe will decrease the TOTAL number of patients receiving chemotherapy (particularly…
Today 25 September 2019, OCB are presenting with IBM at Pharmatec19 – London Room 7 at 11:20 – Using AI Technology To Improve Outcomes For Cancer Patients. OCB aim to benefit cancer patients by implementing advanced precision oncology diagnostics. James Otter,…
Oxford Cancer Biomarkers (OCB) have made another key appointment. The company has hired a Medical Science Liaison Manager to strengthen operations and support continued growth. This follows the accelerating adoption of ToxNav® a comprehensive genetic blood test that identifies cancer…
For immediate release: 22 August 2019 Oxford Cancer Biomarkers (OCB) have hired two Senior Operations and Quality Control Specialists to manage their continued growth, following accelerating adoption of their ToxNav genetic blood test that predicts patients’ susceptibility to 5FU or…
Oxford, UK, 15th July 2019: Oxford Cancer Biomarkers has appointed James Otter as Chief Executive Officer. This represents a key growth milestone for the company which aims to benefit cancer patients through the implementation of advanced precision oncology diagnostics to improve…
Oxford, 21st June 2019: Oxford University Hospitals (OUH) NHS Foundation Trust is now offering genetic testing that aims to prevent chemotherapy toxicity amongst patients who need 5-FU or capecitabine to treat their cancer. This significant improvement in care for…